Across the recent three months, 14 analysts have shared their insights on AbbVie ABBV, expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 12 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 5 | 0 | 0 | 0 |
| 2M Ago | 0 | 4 | 0 | 0 | 0 |
| 3M Ago | 1 | 2 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $201.21, a high estimate of $218.00, and a low estimate of $185.00. This current average reflects an increase of 3.18% from the previous average price target of $195.00.
Exploring Analyst Ratings: An In-Depth Overview
An in-depth analysis of recent analyst actions unveils how financial experts perceive AbbVie. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Christopher Raymond | Piper Sandler | Raises | Overweight | $209.00 | $196.00 |
| Terence Flynn | Morgan Stanley | Raises | Overweight | $218.00 | $211.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $200.00 | $200.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $200.00 | $200.00 |
| Robyn Karnauskas | Truist Securities | Raises | Buy | $210.00 | $195.00 |
| Mohit Bansal | Wells Fargo | Raises | Overweight | $205.00 | $200.00 |
| Carter Gould | Barclays | Raises | Overweight | $200.00 | $187.00 |
| Evan David Seigerman | BMO Capital | Raises | Outperform | $214.00 | $180.00 |
| Terence Flynn | Morgan Stanley | Raises | Overweight | $196.00 | $191.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $200.00 | $200.00 |
| Christopher Raymond | Piper Sandler | Maintains | Overweight | $190.00 | $190.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $200.00 | $200.00 |
| Christopher Raymond | Piper Sandler | Raises | Overweight | $190.00 | $185.00 |
| Rajesh Kumar | HSBC | Announces | Buy | $185.00 | - |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to AbbVie. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AbbVie compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of AbbVie's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on AbbVie analyst ratings.
About AbbVie
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
AbbVie: A Financial Overview
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: AbbVie displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 4.31%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: AbbVie's net margin is impressive, surpassing industry averages. With a net margin of 9.4%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): AbbVie's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 18.4% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): AbbVie's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.94%, the company showcases efficient use of assets and strong financial health.
Debt Management: AbbVie's debt-to-equity ratio surpasses industry norms, standing at 10.42. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
The Core of Analyst Ratings: What Every Investor Should Know
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
